Finally, our findings using the Nrf2 inhibitor ML385 also support the above conclusion and suggest an attractive combination therapy of ACA-28 with an Nrf2 inhibitor to effectively inhibit cancer cell viability. The gene discussed is NFE2L2; the disease is cancer.